INTEGRA LIFESCIENCES HOLDINGS CORP — fact timeline

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Approval of Plan Amendment at the 2026-05-07 meeting.

“Item No. 4: The stockholders approved the Plan Amendment, by the votes set forth below:”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Advisory, non-binding approval of compensation of named executive officers at the 2026-05-07 meeting.

“Item No. 3: The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers, by the votes set forth below.”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 fiscal year at the 2026-05-07 meeting.

“Item No. 2: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year, by the votes set forth below.”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Election of Directors at the 2026-05-07 meeting.

“Item No. 1: All of the nominees for director of the Board of Directors (the “Board”) of the Company were elected to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth below.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported the first quarter ending March 31, 2026 results: revenue $391.9 million, net income $(4.6) million, EPS $(0.06) per diluted share. Guidance raised.

“Total reported revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 55.4%, compared to 50.8% in the first quarter of 2025. Adjusted gross margin was 64.1%, compared to 62.2% in the prior year. Adjusted EBITDA for the first quarter of 2026 was $76.2 million, or 19.4% of revenue, compared to $63.6 million, or 16.6% of revenue, in the prior year. The Company reported a GAAP net loss of $(4.6) million, or $(0.06) per diluted share, in the first quarter of 2026, compared to GAAP net loss of $(25.3) million, or $(0.33) per diluted share, in the prior year.”

Mojdeh Poul departed as Director at INTEGRA LIFESCIENCES HOLDINGS CORP.

“Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").”

Mojdeh Poul departed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").”

Stuart M. Essig was appointed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").”

INTEGRA LIFESCIENCES HOLDINGS CORP entered into April 2026 Amendments with PNC Bank, National Association valued at amendment to $150 million accounts receivable securitization facility (effective 2026-04-10).

“On April 10, 2026, (i) the Borrower and ILS Sales entered into Amendment No. 8 to Receivables Financing Agreement (the “RFA Amendment”), by and among the Borrower, ILS Sales, as Servicer, PNC, as Administrative Agent and Committed Lender, The Bank of Nova Scotia, as Committed Lender and Group Agent, PNC Capital Markets LLC, as Structuring Agent, and certain lenders and group agents that are parties thereto from time to time and (ii) the Borrower and ILS Sales entered into Amendment No. 1 to Purchase and Sale Agreement(the “PSA Amendment,” and together with the RFA Amendment, the “April 2026 Amendments”), by and between the Borrower, as Buyer and ILS Sales, as Servicer, and acknowledged and agreed by PNC, as Administrative Agent.”

Mojdeh Poul was appointed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On November 4, 2024, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Mojdeh Poul to serve as its President and Chief Executive Officer.”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Approval of the Plan Amendment at the 2024-05-09 meeting.

“The stockholders approved the Plan Amendment, by the votes set forth below:”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Amendment to Amended and Restated Certificate of Incorporation to limit liability of certain officers at the 2024-05-09 meeting.

“The stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as permitted by recent amendments to the General Corporation Law of the State of Delaware, by the votes set forth below:”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Advisory (non-binding) approval of executive compensation at the 2024-05-09 meeting.

“The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers, by the votes set forth below.”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2024 at the 2024-05-09 meeting.

“The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2024 fiscal year, by the votes set forth below.”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Election of Directors at the 2024-05-09 meeting.

“All of the nominees for director of the Board of Directors (the “Board”) of the Company were elected to serve until the Company’s 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth below.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported the quarter ended March 31, 2024 results: revenue $368.9 million, net income $(3.3) million, EPS $(0.04) per diluted share. Guidance raised.

“Total reported revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Organic growth excluding Boston was 1.6%. Revenue exceeded the outlook the Company provided in February. The Company reported GAAP gross margin of 56.1%, compared to 61.1% in the first quarter of 2023. Adjusted gross margin was 64.4%, compared to 67.3% in the prior year. Adjusted EBITDA for the first quarter of 2024 was $71.8 million, or 19.5% of revenue, compared to $92.3 million, or 24.2% of revenue, in the prior year. The Company reported a GAAP net loss of $(3.3) million, or $(0.04) per diluted share, in the first quarter of 2024, compared to a GAAP net income of $24.2 million, or $0.29 per diluted share, in the prior year.”

Stuart M. Essig was appointed as Executive Chairman at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On February 27, 2024, the Company’s Board of Directors appointed Stuart M. Essig, Ph.D., the Company’s Chairman, to the role of Executive Chairman, effective immediately.”

Jan De Witte departed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On February 27, 2024, Jan De Witte informed Integra LifeSciences Holdings Corporation (the “Company”) of his intention to retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2024 results: revenue $1,603 million to $1,618 million, EPS $3.15 to $3.25. Guidance initiated.

“For the full-year 2024, the Company expects revenues to be in a range of $1,603 million to $1,618 million, representing reported growth of approximately 4.0% to 5.0% and organic growth in the range of 4.0% to 5.0%. Adjusted earnings per diluted share are expected to be between $3.15 and $3.25.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2023 results: revenue $1,541.6 million, net income $67.7 million, EPS $0.84.

“Total reported revenues for the full-year 2023 were $1,541.6 million, a decrease of 1.0%, from the prior year. Organic sales for the full-year 2023 were flat compared to 2022. Revenue increas ed 5.5% on an organic basis excluding Boston. The Company reported GAAP net income of $67.7 million, or $0.84 per diluted share, for the full-year 2023, compared to GAAP net income of $180.6 million, or $2.16 per diluted share in 2022. Adjusted EBITDA for the full-year 2023 was $369.7 million, a decrease of $41.6 million versus the prior year. Full year EBITDA margins were 24.0% a decrease of 240 basis points from the prior year. Adjusted net income for the full-year 2023 was $247.8 million, or $3.10 per diluted share, compared to $280.9 million, or $3.36 per diluted share.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported fourth quarter 2023 results: revenue 397.0 million, net income $19.8 million, EPS $0.25.

“Total reported revenues for the fourth quarter were 397.0 million, a decrease of 0.2% from the fourth quarter of 2022. Fourth quarter organic revenues were down 1.2% compared to the prior year. Revenue increased 3.6% on an organic basis excluding Boston. The Company reported GAAP net income of $19.8 million, or $0.25 per diluted share, in the fourth quarter of 2023, compared to GAAP net income of $52.9 million, or $0.63 per diluted share, in the prior year. Adjusted EBITDA for the fourth quarter of 2023 was $100.5 million, compared to $109.7 million in the fourth quarter of the prior year. As a percentage of revenue, adjusted EBITDA was 25.3%, a decrease of 230 basis points from the prior year period. Adjusted net income for the fourth quarter of 2023 was $69.1 million, or $0.89 per diluted share, compared to adjusted net income of $78.8 million, or $0.94 per diluted share, in the fourth quarter of 2022.”

INTEGRA LIFESCIENCES HOLDINGS CORP amended Amendment No. 5 to Receivables Financing Agreement and Reaffirmation of Performance Guaranty with PNC Bank, National Association (effective 2023-12-15).

“entered into Amendment No. 5 to Receivables Financing Agreement and Reaffirmation of Performance Guaranty, dated as of December 15, 2023”

INTEGRA LIFESCIENCES HOLDINGS CORP entered into Purchase Agreement with Ethicon, Inc. valued at $275.0 million in cash (effective 2023-12-12).

“On December 12, 2023, Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), entered into a stock purchase agreement (the “Purchase Agreement”) between the Company, Integra LifeSciences Israel Ltd., a private company organized under the laws of the State of Israel and a wholly-owned subsidiary of the Company (“Buyer Israeli Sub”), and Ethicon, Inc., a New Jersey corporation (“Seller”), pursuant to which the Company agreed to acquire all of the outstanding common shares (the “Transferred Shares”) of Acclarent, Inc., a Delaware corporation and wholly-owned subsidiary of Seller (“Acclarent”) for $275.0 million in cash, subject to customary purchase price adjustments, and a cash payment of $5.0 million upon the achievement of a regulatory milestone .”

Jeffrey Alan Graves was appointed as Director at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On December 12, 2023, the Board of Directors (“Board”) of Integra LifeSciences Holdings Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance committee of the Board, appointed Jeffrey Alan Graves as a director of the Company, effective immediately, to fill an existing vacancy on the Board.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported third quarter ending September 30, 2023 results: revenue $382.4 million, net income $19.5 million, EPS $0.24 per diluted share.

“global medical technology company, today reported financial results for the third quarter ending September 30, 2023. Third Quarter 2023 Highlights • Third quarter revenues of $382.4 million declined 0.7% on a reported basis and declined 0.4% on an organic basis compared to the prior year and increased 7.1% on an organic basis excluding Boston • Third quarter GAAP”

INTEGRA LIFESCIENCES HOLDINGS CORP reported the third quarter 2023 results: revenue $386 million to $390 million, EPS $0.76 to $0.80.

“For the third quarter 2023, the Company expects reported revenues in the range of $386 million to $390 million, representing reported growth of 0.2% to 1.3 % and organic growth of 0.3% to 1.3 % . Adjusted earnings per diluted share are expected to be in the range of $0.76 to $0.80”

INTEGRA LIFESCIENCES HOLDINGS CORP reported full year 2023 results: revenue $1.548 billion to $1.560 billion, EPS $3.10 to $3.18.

“Updating full-year 2023 revenue and adjusted earnings per share guidance with a range of $1.548 billion to $1.560 billion and $3.10 to $3.18 respectively”

INTEGRA LIFESCIENCES HOLDINGS CORP reported the quarter ended June 30, 2023 results: revenue $381.3 million, net income $4.2 million, EPS $0.05 per diluted share.

“Total reported revenues of $381.3 million declined 4.2% on a reported basis and declined 2.7% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 54.3%, compared to 62.7% in the second quarter of 2022. Adjusted gross margin was 67.6%, compared to 68.0% in the prior year. Adjusted EBITDA for the second quarter of 2023 was $88.8 million, or 23.3% of revenue, compared to $102.8 million, or 25.8% of revenue, in the prior year. The Company reported GAAP net income of $4.2 million, or $0.05 per diluted share, in the second quarter of 2023, compared to a GAAP net income of $44.8 million, or $0.54 per diluted share, in the prior year.”

Lea Daniels Knight was appointed as Executive Vice President and Chief Financial Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On June 21, 2023, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Lea Daniels Knight to serve as its Executive Vice President and Chief Financial Officer effective June 28, 2023.”

INTEGRA LIFESCIENCES HOLDINGS CORP announced a impairment with charges of approximately $22 million affecting Boston, Massachusetts facility.

“Integra LifeSciences Holdings Corporation (the “Company”), after consultation with the U.S. Food and Drug Administration (the “FDA”), initiated a voluntary global recall of all products manufactured in its Boston, Massachusetts facility (the “Boston facility”) distributed between March 1, 2018 and May 22, 2023 (the “voluntary recall”). As a result, the Company concluded on May 22, 2023 that it expects it will incur an impairment charge related to the write-off of inventories, net, of approximately $22 million.”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-05-12 meeting.

“Item No. 4: The stockholders voted, on an advisory basis, on how frequently future advisory votes on the compensation of the Company’s named executive officers should be held as set forth in the table below. 1 Year 2 Years 3 Years Abstain Broker Non-Vote 75,886,421 3,291 955,372 32,138 2,250,376”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Advisory vote on executive compensation at the 2023-05-12 meeting.

“Item No. 3: The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers, by the votes set forth below. For Against Abstain Broker Non-Vote 73,644,075 3,183,998 49,149 2,250,376”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-12 meeting.

“Item No. 2: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year, by the votes set forth below. For Against Abstain Broker Non-Vote 78,368,495 722,305 36,798 0”

INTEGRA LIFESCIENCES HOLDINGS CORP shareholders approved Election of Directors at the 2023-05-12 meeting.

“Item No. 1: All of the nominees for director of the Board of Directors (the “Board”) of the Company were elected to serve until the Company’s 2024 annual meeting of stockholders or until their respective successors are elected and qualified, by the votes set forth below. Nominees For Against Abstain Broker Non-Vote Keith Bradley 74,622,029 2,199,092 56,101 2,250,376 Shaundra Clay 76,404,281 419,511 53,430 2,250,376 Jan De Witte 75,717,792 1,103,473 55,957 2,250,376 Stuart M. Essig 75,127,004 1,704,299 45,919 2,250,376 Barbara B. Hill 70,176,495 6,647,412 53,315 2,250,376 Renee W. Lo 76,338,362 483,275 55,585 2,250,376 Raymond G. Murphy 74,629,418 2,190,749 57,055 2,250,376 Christian S. Schade 75,358,826 1,460,930 57,466 2,250,376”

INTEGRA LIFESCIENCES HOLDINGS CORP reported the first quarter ended March 31, 2023 results: revenue $380.8 million, net income $24.2 million, EPS $0.29 per diluted share. Guidance reaffirmed.

“Total reported revenues of $380.8 million increased 1.1% on a reported basis and increased 4.6% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 61.1%, compared to 62.1% in the first quarter of 2022. Adjusted gross margin was 67.3%, compared to 67.7% in the prior year. Adjusted EBITDA for the first quarter of 2023 was $92.3 million, or 24.2% of revenue, compared to $93.5 million million, or 24.8% of revenue, in the prior year. The Company reported GAAP net income of $24.2 million, or $0.29 per diluted share, in the first quarter of 2023, compared to a GAAP net income of $32.9 million, or $0.39 per diluted share, in the prior year.”

INTEGRA LIFESCIENCES HOLDINGS CORP incurred credit facility of up to $2.075 billion with Bank of America, N.A., as Administrative Agent at term SOFR plus 0.10% plus the applicable rate (ranging from 1.00% to 1.75%) maturing March 24, 2028.

“On March 24, 2023, Integra LifeSciences Holdings Corporation (the “Company”) entered into an amended and restated credit agreement with a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Citibank N.A., JPMorgan Chase Bank, N.A., Morgan Stanley MUFG Loan Partners, LLC, PNC Bank, N.A., Truist Securities, Inc. and Wells Fargo Bank, N.A., as Co-Syndication Agents, and The Bank of Nova Scotia, BMO Harris Bank N.A., BNP Paribas, Capital One, National Association, Citizens Bank, N.A., DNB Bank ASA, New York Branch, Santander Bank, N.A. and TD Bank, N.A., as Co-Documentation Agents (the “Amendment and Restatement”). The Amendment and Restatement makes an aggregate principal amount of up to $2.075 billion available to the Company through the following facilities: (i) a $1.3 billion revolving credit facility, and (ii) a $775 million term loan facility, which includes a $60 million sublimit for the issuance of standby letters of credit”

INTEGRA LIFESCIENCES HOLDINGS CORP amended Amendment and Restatement with Bank of America, N.A., as Administrative Agent, and a syndicate of lending banks valued at $2.075 billion (effective 2023-03-24).

“On March 24, 2023, Integra LifeSciences Holdings Corporation (the “Company”) entered into an amended and restated credit agreement with a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Citibank N.A., JPMorgan Chase Bank, N.A., Morgan Stanley MUFG Loan Partners, LLC, PNC Bank, N.A., Truist Securities, Inc. and Wells Fargo Bank, N.A., as Co-Syndication Agents, and The Bank of Nova Scotia, BMO Harris Bank N.A., BNP Paribas, Capital One, National Association, Citizens Bank, N.A., DNB Bank ASA, New York Branch, Santander Bank, N.A. and TD Bank, N.A., as Co-Documentation Agents (the “Amendment and Restatement”).”

INTEGRA LIFESCIENCES HOLDINGS CORP reported FY2023 results: revenue $1,602 million to $1,620 million. Guidance initiated.

“For the full-year 2023, the Company expects revenues to be in a range of $1,602 million to $1,620 million, representing reported growth of approximately 2.9% to 4.0% and organic growth in the range of 4.0% to 5.2%.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported FY2022 results: revenue $1,557.7 million, net income $180.6 million, EPS $2.16.

“to $0.53 in the fourth quarter 2021. • Adjusted earnings per diluted share were $0.94, compared to $0.84 in the fourth quarter of 2021. Full-Year 2022 • Reported revenues were 1,557.7 million representing an increase of 1.0% on a reported basis and an increase of 4.2% on an organic basis compared to full-year 2021. • GAAP earnings per diluted share wer e $2.16,”

INTEGRA LIFESCIENCES HOLDINGS CORP reported Q4 2022 results: revenue $398.0 million, net income $52.9 million, EPS $0.63.

“Total reported revenues for the fourth quarter were $398.0 million, a decrease of 1.8% from the fourth quarter of 2021. Fourth quarter organic revenues increased 2.9% over the prior year. The Company reported GAAP net income of $52.9 million, or $0.63 per diluted share, in the fourth quarter of 2022, compared to GAAP net income of $45.4 million, or $0.53 per diluted share, in the prior year.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2022 results: EPS $3.34 to $3.38. Guidance raised.

“Full-year 2022 adjusted earnings per diluted share is expected to be in a range of $3.34 to $3.38 compared to $3.18 in 2021.”

INTEGRA LIFESCIENCES HOLDINGS CORP reported fourth quarter 2022 results: EPS $0.92 to $0.96. Guidance raised.

“Fourth quarter 2022 adjusted earnings per diluted share is expected to be in a range of $0.92 to $0.96 compared to $0.84 in 2021.”

Jeffrey Mosebrook was appointed as Senior Vice President, Finance at INTEGRA LIFESCIENCES HOLDINGS CORP.

“In the interim, Mathieu P. Aussermeier, Vice President, Corporate Finance, Investor Relations & Treasurer, and Jeffrey Mosebrook, Senior Vice President, Finance, will assume Ms. Anderson’s financial duties and responsibilities and report to Jan De Witte, the Company’s President and Chief Executive Officer.”

Mathieu P. Aussermeier was appointed as Vice President, Corporate Finance, Investor Relations & Treasurer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“In the interim, Mathieu P. Aussermeier, Vice President, Corporate Finance, Investor Relations & Treasurer, and Jeffrey Mosebrook, Senior Vice President, Finance, will assume Ms. Anderson’s financial duties and responsibilities and report to Jan De Witte, the Company’s President and Chief Executive Officer.”

Carrie Anderson resigned as Chief Financial Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On January 25, 2023, Carrie Anderson, Chief Financial Officer of Integra LifeSciences Holdings Corporation (the “Company”), notified the Company of her decision to resign, effective as of February 2, 2023, to pursue another professional opportunity.”

INTEGRA LIFESCIENCES HOLDINGS CORP updated its fourth quarter and full-year 2022 guidance (reaffirmed).

“On January 10, 2023, Integra LifeSciences Holdings Corporation (the "Company") issued a press release announcing certain unaudited, preliminary fourth quarter and full-year 2022 financial results.”

Glenn Coleman departed as Chief Operating Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“As previously disclosed, on August 25, 2022, Integra LifeSciences Holdings Corporation (the “Company”) announced the elimination of the position of Chief Operating Officer and the separation of Glenn Coleman, the Company’s Chief Operating Officer, from the Company.”

Glenn Coleman departed as Chief Operating Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“Glenn Coleman, the Company’s current Chief Operating Officer, will cease employment with the Company on that date.”

Renee Wonlai Lo was appointed as director at INTEGRA LIFESCIENCES HOLDINGS CORP.

“On July 18, 2022, the Board of Directors ("Board") of Integra LifeSciences Holdings Corporation (the "Company") appointed Renee Wonlai Lo as a director of the Company, effective immediately, to fill an existing vacancy on the Board.”

Peter J. Arduini resigned as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

“Peter J. Arduini’s previously-announced resignation from his position as President and Chief Executive Officer and a director of the Company became effective as of December 1, 2021.”